Bolin R B
Can J Surg. 1982 Jul;25(4):422-4.
Blood substitutes are being developed that will provide oxygen-transporting capabilities as well as volume replacement. Perfluorochemical and hemoglobin solutions have potential clinical use. A perfluorochemical blood substitute, Fluosol-DA 20%, is being used in clinical trials in several countries. These blood substitutes are not capable of totally replacing the need for blood transfusions but could be used temporarily in situations where blood is contraindicated or not available. They may be useful for a wide range of clinical conditions other than blood replacement, such as impending tissue ischemia. Before large-scale clinical use of these products is realized, more information is needed about drug efficacy and safety so that intelligent decisions can be made about indications for this type of transfusion therapy.
正在研发的血液替代品将具备运输氧气以及补充血容量的能力。全氟化合物和血红蛋白溶液具有潜在的临床应用价值。一种全氟化合物血液替代品，即20%的氟碳乳剂，正在多个国家进行临床试验。这些血液替代品无法完全取代输血的需求，但在血液禁忌或无法获取的情况下可临时使用。它们可能对除输血之外的广泛临床病症有用，比如即将发生的组织缺血。在这些产品大规模临床应用之前，需要更多关于药物疗效和安全性的信息，以便能就这类输血疗法的适应症做出明智决策。
